Cerdulatinib

Last updated
Cerdulatinib
Cerdulatinib.svg
Clinical data
Other namesPRT062070, PRT2070, DMVT-502
Routes of
administration 		By mouth
Identifiers
  • 4-(Cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C20H27N7O3S
Molar mass 445.54 g·mol−1
3D model (JSmol)
  • CCS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4CC4)C(=O)N
  • InChI=1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25) Yes check.svgY
  • Key:BGLPECHZZQDNCD-UHFFFAOYSA-N

Cerdulatinib is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies. [1] It has lowest nM IC50 values against TYK2, JAK1, JAK2, JAK3, FMS, and SYK. [2]

It is being developed by Portola Pharmaceuticals; in September 2018 the FDA granted orphan drug status to cerdulatinib for the treatment of peripheral T-cell lymphoma (PTCL). [3]

See also

References

  1. ↑ Liu D, Mamorska-Dyga A (July 2017). "Syk inhibitors in clinical development for hematological malignancies". Journal of Hematology & Oncology. 10 (1): 145. doi: 10.1186/s13045-017-0512-1 . PMC   5534090 . PMID   28754125.
  2. ↑ Coffey G, Betz A, DeGuzman F, Pak Y, Inagaki M, Baker DC, et al. (December 2014). "The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer". The Journal of Pharmacology and Experimental Therapeutics. 351 (3): 538–48. doi: 10.1124/jpet.114.218164 . PMID   25253883.
  3. ↑ "Investors - News Release - Portola Pharmaceuticals, Inc". phx.corporate-ir.net. September 25, 2018.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.